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Background: Recently, a phase II clinical trial in hepatocellular carcinoma (HCC) has suggested that the combination
of sorafenib and 5-fluorouracil (5-FU) is feasible and side effects are manageable. However, preclinical experimental
data explaining the interaction mechanism(s) are lacking. Our objective is to investigate the anticancer efficacy and
mechanism of combined sorafenib and 5-FU therapy in vitro in HCC cell lines MHCC97H and SMMC-7721.
Methods: Drug effects on cell proliferation were evaluated by cell viability assays. Combined-effects analyses were
conducted according to the median-effect principle. Cell cycle distribution was measured by flow cytometry.
Expression levels of proteins related to the RAF/MEK/ERK and STAT3 pathways and to cell cycle progression (cyclin D1)
were determined by western blot analysis.
Results: Sorafenib and 5-FU alone or in combination showed significant efficacy in inhibiting cell proliferation in both
cell lines tested. However, a schedule-dependent combined effect, associated with the order of compound treatments,
was observed. Efficacy was synergistic with 5-FU pretreatment followed by sorafenib, but it was antagonistic with the
reverse treatment order. Sorafenib pretreatment resulted in a significant increase in the half inhibitory concentration
(IC50) of 5-FU in both cell lines. Sorafenib induced G1-phase arrest and significantly decreased the proportion of cells in
S phase when administrated alone or followed by 5-FU. The RAF/MEK/ERK and STAT3 pathways were blocked and
cyclin D1 expression was down regulated significantly in both cell lines by sorafenib; whereas, the kinase pathways
were hardly affected by 5-FU, and cyclin D1 expression was up regulated.
Conclusions: Antitumor activity of sorafenib and 5-FU, alone or in combination, is seen in HCC cell lines. The nature
of the combined effects, however, depends on the particular cell line and treatment order of the two compounds.
Sorafenib appears to reduce sensitivity to 5-FU through down regulation of cyclin D1 expression by inhibiting
RAF/MEK/ERK and STAT3 signaling, resulting in G1-phase arrest and reduction of the S-phase cell subpopulation
when 5-FU is administrated after sorafenib, in which situation, combination treatment of the two agents results in
antagonism; on the other hand, when sorafenib is administrated afterward, it can continue to work since it is not cell
cycle specific, as a result, combination treatment of the two agents shows an additive-to-synergistic effect.
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Hepatocellular carcinoma (HCC) is the sixth most common
malignancy worldwide and ranks as the third leading cause
of cancer-related death, accounting for 748,300 new cases
and 695,900 deaths worldwide per year. Half of these cases
and deaths are estimated to occur in China [1]. However,
only approximately 30%–40% of patients are diagnosed in
an early stage (0 or A) according to the Barcelona Clinic
Liver Cancer staging system [2], which defines patients who
are suitable for potentially curative approaches, such as
surgical therapies (resection and liver transplantation) and
locoregional procedures (radiofrequency ablation). For
patients who meet the criteria for the intermediate
stage (multinodular HCC, relatively preserved liver
function, absence of cancer-related symptoms, and no
evidence of vascular invasion or extrahepatic spread),
transcatheter arterial chemoembolization (TACE) has been
established as the standard of care, and this treatment may
achieve a partial response or complete necrosis [3].
For patients with advanced HCC, sorafenib is the first
agent discovered to result in favorable overall survival
[4]. Regional hepatic arterial infusion chemotherapy
(HAIC) has also been used in patients with advanced
HCC in cases in which TACE is not indicated or is
ineffective [5,6].
The technique of TACE, including which drug is
administrated, the scheduled followed after the first TACE
or the follow-up imaging modalities, varies worldwide
with no clear consensus. Among the agents commonly
used in TACE and HAIC to inhibit cancer cell growth,
5-Fluorouracil (5-FU) is a widely used chemotherapeutic
drug. It initiates apoptosis by targeting thymidylate synthase
(TS) and direct incorporation of 5-FU metabolites into
DNA and RNA. However, its efficacy in HCC is poor [7],
and the compound is associated with acquired and intrinsic
resistance.
Sorafenib (BAY 43-9006, Nexavar) is an oral multikinase
inhibitor that inhibits the serine-threonine kinases C-Raf
and B-Raf, the receptor tyrosine kinase activity of vascular
endothelial growth factor receptors -1, -2, and -3, platelet-
derived growth factor receptor β, the receptor for the
macrophage-colony stimulating factor (FLT3), Ret, and
c-Kit. These kinases are involved in cell proliferation and
tumor angiogenesis [8,9]. In addition, increasingly more
studies have pointed out that signal transducer and
activator of transcription 3 (STAT3) is a major kinase-
independent target of sorafenib in HCC [10,11].
Recently, a phase II clinical trial has suggested that the
combination of sorafenib and 5-fluorouracil is feasible,
and the side effects are manageable for patients carefully
selected for liver function and performance status [12].
However, preclinical experimental data explaining inter-
action mechanisms are widely missing. One previous
study in our institute found that resistance to 5-FU wassignificantly associated with basal p-ERK expression
levels in HCC cell lines while sorafenib inhibited ERK
phosphorylation in a dose-dependent manner [13]. Chances
are combination of sorafenib and 5-FU would exert a
synergetic effect with the hypothesis that sorafenib
could reverse the resistance to 5-FU of HCC cells by
inhibiting p-ERK expressions. However, it is known that
5-FU is an S-phase-specific agent, whereas sorafenib
causes G1-phase arrest in tumor cells [14]. The latter
implies that sorafenib treatment would decrease the
proportion of cells in S phase. And in such situation,
tumor cells might become less susceptible to the 5-FU
action. Therefore, the effects of combined sorafenib and
5-FU co-administration are uncertain.
In the present study, we initiated an in vitro study in
HCC cell lines MHCC 97H and SMMC-7721 to investigate
the anticancer efficacy and molecular mechanisms of





purchased from BioVision, Inc. (Milpitas, CA, USA). The
compound was dissolved in 100% dimethyl sulfoxide
(DMSO; Sigma-Aldrich, St Louis, MO, USA) and diluted
with Dulbecco's modified Eagle's medium (DMEM) or
RPMI 1640 to the desired concentration; a final DMSO
concentration of 0.1% (v/v) was present in cell studies. As
solvent control, 0.1% DMSO alone was added to cultures.
5-Fluorouracil injection was purchased from Shanghai
Xudong Haipu Pharmaceutical Co, Ltd. (Shanghai, China)
and was diluted directly with cell culture medium to the
desired concentration.
Cell lines
Human HCC tumor cell lines MHCC97H and SMMC-7721
were obtained from the Liver Cancer Institute of Fudan
University (Shanghai, China) and cultured in DMEM
or RPMI 1640 containing 10% v/v fetal bovine serum at
37°C in a humidified incubator containing 5% CO2. Unless
otherwise indicated, cell culture reagents were purchased
from GIBCO BRL (Grand Island, NE, USA).
Cell viability assay
Cells were plated in 96-well microtiter plates (4,000 per
well) in 100 μL of serum-containing medium and incubated
overnight at 37°C in the culture incubator. On the following
day, the medium was replaced with fresh medium con-
taining sorafenib, 5-FU, or a combination of the two agents
at various concentrations. Treatment with sorafenib was
done for 24 h at concentrations of 0, 0.25, 0.5, 1, 4, 8, 16,
32, 64, or 128 μM; that with 5-FU was for 48 h at concen-
trations of 0, 0.1, 1, 2, 4, 8, 16, 32, 64, 128, or 256 mg/L. Cell
Figure 1 Antitumor effects of sorafenib and 5-fluorouracil (5-FU), alone or in combination, in hepatocellular carcinoma (HCC) cell lines.
(A) Dose–response curves, correlating drug dose and cell viability, depict the effects of sorafenib and 5-FU on different HCC cell lines.
The cell survival fraction is expressed relative to the untreated cells, set at 100. (B) Antiproliferation effects of 5-FU (4 mg/L, 48 h) and
sorafenib (8 μM, 24 h), alone or in combination in different treatment sequences, in HCC cell lines. The cell numbers are represented as
optical density (OD) values. (C) Inhibition rates of 5-FU (4 mg/L, 48 h) or sorafenib (8 μM, 24 h), alone or in combination in different
treatment sequences, in HCC cell lines. The cell inhibition fraction is expressed relative to the untreated cells, set at 100. In this figure,
values represent the mean ± standard deviation (SD), and each is the average of three independent determinations, with six replicates
per experiment. S, sorafenib; F, 5-FU.
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http://www.biomedcentral.com/1471-2407/13/363viability was measured using the Cell Counting Kit-8
(Dojindo Laboratories, Kumamoto, Japan) according to the
manufacturer's instructions. The half maximal inhibitoryconcentration (IC50) values were calculated by nonlinear
regression analysis using GraphPad Prism version 5.0
software (GraphPad Software, Inc., San Diego, CA, USA).
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the median effect analysis method. A synergistic effect is
defined as CI < 1, an additive effect as CI = 1, and an
antagonistic effect as CI > 1.
Each condition was tested six times, and the results
were confirmed in at least three independent experiments.
To further investigate combined effects of sorafenib
and 5-FU on cell proliferation, growth inhibition, cell
cycle distribution and pathways activities, six treatment
groups were designed as follows: group control (0.1%
DMSO); group S (treatment with 8 μM sorafenib for
24 h); group F (treatment with 4 mg/L 5-FU for 48 h);
group (S + F) (concurrent treatment with 8 μM sorafenib
and 4 mg/L 5-FU for 48 h); group S + F (8 μM sorafenib
pretreatment for 24 h followed by 4 mg/L 5-FU treatment
for another 48 h); group F + S (4 mg/L 5-FU treatment
followed by 8 μM sorafenib for another 24 h).
Cell cycle assays
Exponentially growing cells were starved in serum-free
medium for 24 h, after which they were grown in
medium containing 10% serum with the compounds
8 μM sorafenib for 24 h or 4 mg/L 5-FU for 48 h, either
alone or in combination patterns. Cell cycle analyses and
quantification of genomic DNA fragmentation were
performed using the Cell Cycle Detection Kit (KeyGEN,
Nanjing, China) according to the manufacturer’s protocol.
Cell cycle distributions were analyzed by flow cytometry
with a Becton Dickinson FACS Calibur.
Western blot analysis
To prepare whole-cell protein extracts, cells were washed
twice with phosphate-buffered saline and then lysed with a
modified radio-immunoprecipitation assay buffer (50 mM
Tris–HCl pH 7.4, 1% v/v NP-40, 0.25% v/v sodium
deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF,
1 mg/mL of protease inhibitors (leupeptin and pepstatin),
1 mM Na3VO4, and 1 mM NaF) on ice for 30 min.
Insoluble material was removed by centrifugation at 12,000
p/min for 15 min at 4°C. The protein concentration of cell
lysates was measured using the Bradford Protein Assay Kit
(Beyotime, Shanghai, China), and 30 μg of protein samples
were loaded on 10% polyacrylamide gels containing sodium
dodecyl sulfate and separated by electrophoresis at a
constant voltage of 70 V for 2 h and transferred onto
0.45-μm polyvinylidene fluoride membranes (MilliporeTable 1 Inhibition rates (% of control) of sorafenib and 5-fluo
carcinoma (HCC) cells
Cell line S F (S + F)/p-va
MHCC97H 18.63 ± 3.82 33.30 ± 5.67 29.87 ± 8.83
SMMC-7721 20.60 ± 3.83 29.65 ± 4.74 30.35 ± 4.86
S: sorafenib, F: 5-FU.Corporation, Billerica, MA, USA) at a constant voltage of
100 V for 3 h at 0°C. The membranes were probed with
the specific primary antibodies followed by a horseradish
peroxidase-conjugate secondary antibody (1:5,000) and
detected by enhanced chemiluminescence (ECL kit from
Pierce, Rockford, IL, USA). The following primary anti-
bodies were used: anti-C-RAF (1:1,000), anti-phospho-C-
RAF (1:1,000), anti-ERK1/2 (1:1,000), and anti-phospho-
ERK1/2 (Thr202/Tyr204) (1:1,000) from Cell Signaling
Technology, Inc. (Danvers, MA, USA); anti-STAT-3
(1:1,000) and anti-phospho-STAT-3 (Tyr705) (1:1,000) from
Abcam (Cambridge, MA, USA); and anti-cyclin D1 (1:1000)
and anti-β-actin from Beyotime. Unless otherwise indicated,
immunoblot reagents were purchased from Beyotime.
Statistical analysis
Statistical analysis was performed with SPSS 17.0 software
(SPSS, Chicago, IL, USA). Measured values are expressed
as mean ± standard deviation. Analysis of variance and
least significant difference were used to evaluate statistical
significance of differences between groups, and a P value
of <0.05 was considered statistically significant.
Results
Antitumor effects of sorafenib and 5-FU in HCC cell lines
Sorafenib and 5-FU both inhibited cell proliferation of
the two HCC cell lines in a dose-dependent manner.
The IC50 values of sorafenib were 17.82 ± 2.04 μM and
15.52 ± 0.95 μM in MHCC97H and SMMC-7721 cells,
respectively, and the corresponding IC50 values of 5-FU
were 116.59 ± 62.04 mg/L and 47.19 ± 13.02 mg/L,
respectively. The dose–response curves for the two
HCC cell lines are shown in Figure 1(A).
To evaluate the combined effects of sorafenib and 5-FU
on cell proliferation and growth inhibition, six treatment
groups were designed as in section “Methods”. The cell pro-
liferation conditions of the six groups are shown in Figure 1
(B), and inhibition rates of the six groups are listed in Figure 1
(C) and Table 1. Our results generally suggest that inhibitory
effects were equipotent to 5-FU monotherapy when 5-FU
was concurrently administrated with sorafenib, better in the
5-FU-pretreated sequence, and, conversely, worse in the
sorafenib pretreatment schedule (P values are shown in
Table 1). That is, sequential treatment using 5-FU followed
by sorafenib seems to be the optimal schedule for com-
bined administration of the two agents.rouracil (5-FU), alone or in combination, in hepatocellular
lue(vs. F) S + F/p-value(vs. F) F + S/p-value(vs. F)
/p = 0.328 22.98 ± 5.93/p = 0.023 42.57 ± 3.29/p = 0.017
/p = 0.781 23.23 ± 4.43/p = 0.016 53.50 ± 1.97/p = 0.000
Table 2 Combination index (CI) values of sorafenib and 5-fluorouracil (5-FU) combination in different treatment






(S + F) S + F F + S (S + F) S + F F + S
1 0.5 4.33 ± 1.73 32.84 ± 4.26 3.88 ± 1.73 112.45 ± 28.23 67.40 ± 15.67 13.63 ± 9.81
2 1 2.07 ± 0.44 9.70 ± 3.96 5.20 ± 2.17 1.95 ± 1.01 13.50 ± 9.43 0.50 ± 0.34
4 2 1.47 ± 0.25 3.69 ± 2.08 3.25 ± 2.57 1.33 ± 0.38 1.80 ± 0.11 0.41 ± 0.20
8 4 1.18 ± 0.28 2.33 ± 1.24 1.13 ± 0.27 1.45 ± 0.33 1.66 ± 0.17 0.38 ± 0.05
16 8 0.99 ± 0.40 1.26 ± 0.30 0.75 ± 0.15 1.02 ± 0.09 1.71 ± 0.06 0.40 ± 0.04
CI Combination index. CI < 1 indicate synergy between the drugs; CI = 1 indicates additivity; and CI > 1 indicates antagonism. Values are expressed as the
mean ± SD of at least three independent experiments performed in triplicate. S: sorafenib, F: 5-FU.
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with 5-FU results in synergism, additivity, or antagonism of
inhibition of cell proliferation, combination index (CI)
values were calculated using the median effect analysis
method [15]. Sorafenib and 5-FU were administrated at
certain concentration ratios in different sequences. The CI
values are summarized in Table 2. Our data indicate that
combination treatment of sorafenib and 5-FU largely
resulted in antagonism in MHCC97H cells regardless of
treatment order, with a degressive trend as drug concentra-
tions increase. Further analysis indicated that the CI values
of the 5-FU-pretreated group were smaller than those
of the sorafenib-pretreated group and drew near 1 as
drug concentrations increased, which indicated an
additive-to-synergistic effect. Situations in SMMC-7721
cells were similar except that pretreatment with 5-FU
showed an apparent synergistic effect.
Sensitivity of HCC cells to 5-FU in combination with
sorafenib
The sensitivity of HCC cell lines to 5-FU was determined
by calculating the IC50 values from results of cell viability
assays. In these experiments, four treatment groups were
tested: group F (single treatment with 5-FU); group (S + F)Figure 2 Sensitivity of hepatocellular carcinoma (HCC) cells to 5-fluor
in vitro. Dose–response curves of 5-FU alone and combined with sorafeni
MHCC97H (A) and SMCC-7721 (B) were exposed to escalating doses of 5-F
sequences. The cell survival fraction is expressed relative to the untreated c
represents the average of three independent determinations with six replic(concurrent treatment with 5-FU and 8 μM sorafenib);
group S + F (8 μM sorafenib pretreament for 24 h followed
by 5-FU treatment); and group F + S (5-FU pretreat-
ment followed by 8 μM sorafenib for another 24 h).
Dose–response curves are shown in Figure 2, and
IC50 values for 5-FU treatment of the four groups are listed
in Table 3. Sensitivity to 5-FU varied greatly, depending on
compound treatment order: sorafenib dramatically de-
creased the sensitivity to 5-FU when it was administrated
prior to 5-FU, with the IC50 values increasing significantly
(P < 0.001 for both) in both MHCC97H and SMMC-7721
cells. Conversely, the IC50 values of 5-FU decreased in both
cell lines when sorafenib was administrated afterward.
Effects of sorafenib and 5-FU on cell cycle progress in
HCC cell lines
Six treatment groups (group control, S, F, (S + F), S + F, and
F + S, as described above) were tested. Cell cycle distribu-
tions are shown in Figure 3 and Tables 4 and 5. Our data
indicate that sorafenib induced a G1-cell cycle arrest and
significantly decreased the proportion of cells in S phase in
both HCC cell lines when it was administrated alone or
followed by 5-FU: proportions of cells in G1 phase in-
creased from 47.53 ± 0.06% to 63.03 ± 0.95% and 66.70 ±ouracil (5-FU) when treated in combination with sorafenib
b, in different treatment sequences, are shown. HCC cell lines
U, alone or combined with 8 μM sorafenib, in different treatment
ells, set at 100, and is expressed as the mean ± SD. Each value
ates per experiment. Bars indicate standard error. S, sorafeinb; F, 5-FU.
Table 3 Sensitivity of hepatocellular carcinoma (HCC) cells to 5-fluorouracil (5-FU) (IC50 of 5-FU (mg/L)) in different
treatment strategies
Cell line F (S + F)/p-value (vs. F) S + F/p-value (vs. F) F + S/p-value (vs. F)
MHCC97H 116.59 ± 62.04 271.63 ± 57.08/p = 0.002 477.46 ± 146.45/p = 0.000 25.45 ± 9.72/p = 0.042
SMMC-7721 47.19 ± 13.02 43.16 ± 8.76/p = 0.948 1371.26 ± 237.70/p = 0.000 9.47 ± 1.03/p = 0.568
S: sorafenib, F: 5-FU.
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and proportions of cells in S phase decreased from 40.97 ±
0.15% to 17.43 ± 0.85% and 12.27 ± 0.45% (P < 0.001 for
both) in MHCC97H cells. For SMMC-7721 cells, propor-
tions of cells in G1 phase increased from 63.83 ± 1.94% to
70.07 ± 0.70% and 81.83 ± 0.35% respectively (P < 0.001 for
both) and proportions of cells in S phase decreased from
27.17 ± 2.41% to 8.45 ± 1.03% and 9.23 ± 0.12% respectively
(P < 0.001 for both). Simultaneous treatment or pretreat-
ment with 5-FU reversed this effect to some extent.
Activation of RAF/MEK/ERK and STAT3 pathways and
expression of cyclin D1
To identify the molecule mechanism of interactions be-
tween sorafenib and 5-FU, expression levels of proteinsFigure 3 Effects of sorafenib and 5-fluorouracil (5-FU) on cell cycle pr
MHCC97H (A) and SMMC-7721 (B). After serum starvation for 24 h, cells
combination treatments of the two agents. The cell cycle distributions werrelated to RAF/MEK/ERK and STAT3 pathways and to cell
cycle progression (cyclin D1) were measured. Results
showed that the levels of phosphorylated C-RAF, ERK, and
STAT3 were significantly down regulated after sorafenib
treatment in both cell lines (P < 0.001). Similar results were
observed when sorafenib was concurrently administrated
with 5-FU. Sequential therapies as well showed down-
regulatory effects on expression of these proteins, although
the differences were less than seen with sorafenib mono-
therapy. These pathways remained unchanged after exposure
to 5-FU monotherapy. Moreover, sorafenib significantly
down regulated cyclin D1 expression (P < 0.001), while 5-FU
played an opposite role in both cell lines. Combined treat-
ments also induced cyclin D1 down regulation, although the
differences were less significant (Figure 4, Tables 6 and 7).ogression in the hepatocellular carcinoma (HCC) cell lines
were exposed to sorafenib (8 μM, 24 h), 5-FU (4 mg/L, 48 h), or
e then analyzed by flow cytometry. C, control; S, sorafeinb; F, 5-FU.
Table 4 Cell cycle distribution of MHCC97H cells after different drug treatments
G1 phase (%)/p-value (vs. control) S phase (%)/p-value (vs. control) G2/M phase (%)/p-value (vs. control)
Control 47.53 ± 0.06 40.97 ± 0.15 11.50 ± 0.20
S 63.03 ± 0.95/p = 0.000 17.43 ± 0.85/p = 0.000 19.50 ± 0.10/p = 0.000
F 62.60 ± 0.70/p = 0.000 25.23 ± 0.72/p = 0.000 12.17 ± 1.95/p = 0.367
(S + F) 60.50 ± 0.50/p = 0.000 22.00 ± 0.10/p = 0.000 17.47 ± 0.35/p = 0.000
S + F 66.70 ± 0.30/p = 0.000 12.27 ± 0.45/p = 0.000 21.03 ± 0.75/p = 0.000
F + S 64.30 ± 1.10/p = 0.000 32.80 ± 1.00/p = 0.000 2.91 ± 0.07/p = 0.000
S: sorafenib, F: 5-FU.
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Though few basic scientific studies have provided
substantial evidence about the activity of 5-FU in
combination with sorafenib in HCC, combined effects
of the two agents on other solid tumors are controversial.
Thomas and colleagues [16] have shown that single-agent
therapy with sorafenib or 5-FU is equally effective in
human colorectal cancer, and combination therapy shows
no additional effect. On the other hand, a recent study
demonstrates that combination therapy of 5-FU and
sorafenib exerts a synergistic antitumor effect in renal cell
carcinoma [17]. As sorafenib and 5-FU are both commonly
used in HCC patients, it is meaningful and instructive to
investigate the combined effects in HCC cells.
We find that both sorafenib and 5-FU display
antitumor effects in the HCC cell lines MHCC97H and
SMMC-7721. Combined effects of the two agents are
schedule-dependent: concurrent treatment shows similar
efficacy, while pretreatment with sorafenib exacerbates
inhibitory effects, but 5-FU pretreatment followed by
sorafenib ameliorates inhibitory effects compared with
5-FU monotherapy. According to variations in IC50
values, we find that HCC cells become less sensitive to
5-FU after pretreatment with sorafenib, yet more sensi-
tive when 5-FU pretreatment is followed by sorafenib.
That is to say, sequential treatment of 5-FU followed by
sorafenib seems to be the optimal schedule for com-
bined administration of the two agents.
Manov and colleagues [18] found that sorafenib, when
combined with doxorubicin, increased survival and reduced
doxorubicin-induced autophagy by inhibiting MEK/ERK
and inducing degradation of cyclin D1 in the HCC cell lineTable 5 Cell cycle distribution of SMMC-7721 cells after differ
G1 phase (%)/p-value (vs control) S phase (%
Control 63.83 ± 1.94
S 70.07 ± 0.70/p = 0.000 8.45
F 72.23 ± 0.35/p = 0.000 25.50
(S + F) 64.73 ± 0.15/p = 0.458 29.90
S + F 81.83 ± 0.35/p = 0.000 9.23
F + S 71.22 ± 2.80/p = 0.000 27.20
S: sorafenib, F: 5-FU.Hep3B. Based on these results, they believe that the use of
MEK/ERK inhibitors in combination with chemotherapeu-
tics might have possible antagonistic effects. Our results
tend to lead to a similar conclusion. Thus, we have tried to
understand the mechanism by examining some of the
sorafenib-related pathways, like the STAT3 and RAF/MEK/
EKR cascade. In addition, we have analyzed cell cycle distri-
bution and expression of proteins associated with cell cycle
progression, as it is known that 5-FU is an S-phase-specific
chemotherapeutic drug.
Our data reveal that sorafenib efficiently blocks STAT3
and RAF/MEK/EKR pathways, showing down regulation
of p-C-RAF, p-ERK, and p-STAT3, while 5-FU shows
almost no effect. No changes were observed for total
C-RAF, ERK and STAT3 proteins by any of the treatments.
Furthermore, sorafenib slows cell cycle progression by
inducing a G1-phase arrest, which results in a reduction
of the S-phase subpopulation. Sorafenib significantly down
regulates cyclin D1 expression in HCC cells, while 5-FU
has an opposite effect. Since expression levels of cyc-
lin D1 in combination groups were as well down-
regulated, we believe that sorafenib plays a dominant
role in regulating cell cycle distributions and cyclin
D1 expressions in combined treatments of sorafenib
and 5-FU.
Signaling through RAF⁄MEK⁄ERK plays a crucial role in
cell proliferation, differentiation, malignant transformation,
and apoptosis [19,20]. It has been thoroughly demonstrated
that sorafenib exhibits remarkable antitumor activity in
HCC in vitro and in vivo, through targeting the RAF/MEK/
EKR cascade [21,22]. Our results agree well with these
reports.ent drug treatments
)/p-value (vs control) G2/M phase (%)/p-value (vs control)
27.17 ± 2.41 9.00 ± 2.26
± 1.03/p = 0.000 21.51 ± 1.63/p = 0.000
± 0.80/p = 0.188 2.27 ± 1.15/p = 0.000
± 0.10/p = 0.041 5.37 ± 0.27/p = 0.004
± 0.12/p = 0.000 8.92 ± 0.44/p = 0.939
± 2.30/p = 0.978 1.08 ± 0.40/p = 0.000
Figure 4 Activation of RAF/MEK/ERK and STAT3 pathways and expression levels of cyclin D1 after treatment with sorafenib and
5-fluorouracil (5-FU). Cells were treated with sorafenib (8 μM, 24 h), 5-FU (4 mg/L, 48 h), or combination of the two agents in different treatment
sequences. Western blot analysis was performed to detect the expression levels of p-C-RAF, total C-RAF, p-ERK1/2, total ERK1/2, p-STAT3 (Y705),
total STAT3, and cyclin D1. Loading controls were carried out by probing the blots for β-actin. Representative western blots (A) and quantification
analysis (B and C) are shown. Asterisks (*) indicate significant differences in protein expression (P < 0.05). C, control; S, sorafeinb; F, 5-FU.
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p-C-RAF 1 0.47 ± 0.10/p = 0.000 0.95 ± 0.06/p = 0.544 0.43 ± 0.07/p = 0.000 0.68 ± 0.12/p = 0.003 0.61 ± 0.18/p = 0.001
C-RAF 1 0.95 ± 0.06/p = 0.336 0.97 ± 0.09/p = 0.631 0.98 ± 0.08/p = 0.703 0.95 ± 0.07/p = 0.386 1.02 ± 0.07/p = 0.737
p-ERK1/2 1 0.47 ± 0.05/p = 0.000 0.96 ± 0.04/p = 0.200 0.45 ± 0.05/p = 0.000 0.64 ± 0.04/p = 0.000 0.54 ± 0.01/p = 0.000
ERK1/2 1 0.92 ± 0.06/p = 0.099 0.95 ± 0.05/p = 0.255 1.00 ± 0.07/p = 0.965 0.93 ± 0.05/p = 0.133 0.98 ± 0.06/p = 0.611
p-STAT3(Y705) 1 0.38 ± 0.05/p = 0.000 0.96 ± 0.03/p = 0.193 0.38 ± 0.02/p = 0.000 0.43 ± 0.06/p = 0.000 0.40 ± 0.05/p = 0.000
STAT3 1 0.97 ± 0.21/p = 0.734 0.92 ± 0.05/p = 0.416 0.93 ± 0.05/p = 0.417 0.95 ± 0.12/p = 0.612 0.97 ± 0.08/p = 0.720
Cyclin D1 1 0.56 ± 0.05/p = 0.002 1.55 ± 0.29/p = 0.000 0.64 ± 0.12/p = 0.008 0.70 ± 0.09/p = 0.023 0.61 ± 0.07/p = 0.004
C: control, S: sorafenib, F: 5-FU.
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http://www.biomedcentral.com/1471-2407/13/363The STAT3 proteins have dual roles as cytoplasmic
signaling proteins and nuclear transcription factors that
activate a diverse set of genes, including some that are
importantly implicated in tumor cell proliferation, survival,
invasion, cell-cycle progression, tumor angiogenesis, and
tumor cell evasion of the immune system [23-25]. Recently,
sorafenib has been shown to suppress tumor growth by
decreasing STAT3 phosphorylation in a group of human
malignancies [26-29], including HCC [11,30]. As the results
we obtained from tests of STAT3 activation after sorafenib
treatment are in line with previous studies, we have gained
further insight into the mechanism of anti-cancer effects of
sorafenib.
It is well known that key genes in cell-cycle control,
such as cyclin D1, an important regulator of G1-to-S
phase progression [31], are regulated by STAT3 [25,26].
In addition, some studies have demonstrated that cyclin
D1 is regulated by both the RAF⁄ MEK⁄ ERK and
phosphoinositide-3 kinase (PI3K)/Akt pathways [32,33].
Interestingly, some recent studies point out that
sorafenib inhibits growth and metastasis of HCC in part
by blocking the MEK/ERK/STAT3 and PI3K/Akt/
STAT3 signaling pathways [11]; and that sorafenib-induced
Tyr705 STAT3 dephosphorylation is mediated by Raf in-
hibition, as the Raf-inhibitor ZM336372 also results in
Tyr705 STAT3 dephosphorylation [34]. Therefore, we have
reasons to believe that STAT3 somehow functions down-





p-C-RAF 1 0.47 ± 0.12/p = 0.000 0.93 ± 0.06/p = 0.185
C-RAF 1 0.90 ± 0.08/p = 0.154 1.07 ± 0.12/p = 0.302
p-ERK1/2 1 0.54 ± 0.03/p = 0.000 1.06 ± 0.12/p = 0.403
ERK1/2 1 1.00 ± 0.06/p = 0.971 1.08 ± 0.09/p = 0.193
p-STAT3(Y705) 1 0.51 ± 0.02/p = 0.000 0.95 ± 0.06/p = 0.180
STAT3 1 1.03 ± 0.03/p = 0.627 1.06 ± 0.07/p = 0.376
Cyclin D1 1 0.53 ± 0.08/p = 0.000 1.83 ± 0.18/p = 0.000
C: control, S: sorafenib; F: 5-FU.A recent study has indicated that 5-FU resistance in
oral squamous cell carcinoma (OSCC) cell lines HSC-3 and
CA9-22, both of which are hypoxia-sensitive (HS), is due to
suppressed growth rate and G1-phase accumulation [35].
Similarly, we find that sorafenib causes a G1-phase arrest of
HCC cells and, as well, decreases sensitivity to 5-FU,
leading to an antagonistic effect of the two agents in
the sorafenib-pretreatment strategy.
To summarize, combination effects of sorafenib and
5-FU vary between the different treatment orders. On the
whole, antitumor effects are highest in 5-FU pretreatment
strategies, and they are lowest following sorafenib pretreat-
ment patterns. Since 5-FU is an S-phase-specific chemo-
therapeutic drug, it works less efficiently after exposure to
sorafenib because of reduction in the proportion of S-phase
cells. In contrast, sorafenib exerts further antitumor effects
after 5-FU treatments, as the mechanism of sorafenib is cell
cycle-independent.
Our in vitro study is limited to the cellular level, and
in vivo studies are needed that cover sequential therapy
of cell cycle-dependent chemotherapeutic drugs and
molecular-targeted drugs. Still, our results do provide
some important clues that may help guide drug selection
and therapeutic strategy used in clinical treatments.
Conclusions
From our experimental results and what is known in the







0.40 ± 0.07/p = 0.000 0.64 ± 0.04/p = 0.000 0.61 ± 0.05/p = 0.000
0.95 ± 0.06/p = 0.431 1.05 ± 0.10/p = 0.459 1.06 ± 0.08/p = 0.408
0.66 ± 0.09/p = 0.000 0.77 ± 0.03/p = 0.005 0.63 ± 0.05/p = 0.000
0.94 ± 0.07/p = 0.307 1.09 ± 0.07/p = 0.141 1.00 ± 0.08/p = 0.996
0.63 ± 0.06/p = 0.000 0.82 ± 0.03/p = 0.000 0.78 ± 0.06/p = 0.000
1.03 ± 0.13/p = 0.621 1.08 ± 0.12/p = 0.235 1.10 ± 0.05/p = 0.135
0.57 ± 0.04/p = 0.000 0.89 ± 0.07/p = 0.174 0.76 ± 0.05/p = 0.008
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http://www.biomedcentral.com/1471-2407/13/363possess antitumor activity in HCC cells; (2) compared
with 5-FU monotherapy, combination treatment with
sorafenib and 5-FU shows weaker effects when sorafenib
is followed by 5-FU, while the effect is stronger
when 5-FU is followed by sorafenib; and (3) sorafenib
pretreatment reduces the sensitivity of HCC cells to
5-FU by down regulating cyclin D1 expression via
inhibition of RAF/MEK/ERK and STAT3 signaling,
which in turn results in G1-phase arrest and S-phase
reduction.
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